WO2026024841 protease-activated CD3×MUC1 bispecific antibodies with dual masking of both arms. They remain inactive systemically, activate within the tumour microenvironment, reducing toxicity and maintaining efficacy, including in low-MUC1 tumours. The platform is modular for other tumour antigens.
February 12, 2026 at 12:33 PM
WO2026024841 protease-activated CD3×MUC1 bispecific antibodies with dual masking of both arms. They remain inactive systemically, activate within the tumour microenvironment, reducing toxicity and maintaining efficacy, including in low-MUC1 tumours. The platform is modular for other tumour antigens.
Hypoxia-driven #VEGF secretion promotes resistance to bispecific T-cell engagers by suppressing T-cell function, identifying VEGF inhibition as a viable strategy to enhance #Immunotherapy in #SolidTumors. @harvardmed.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
February 12, 2026 at 12:30 PM
Hypoxia-driven #VEGF secretion promotes resistance to bispecific T-cell engagers by suppressing T-cell function, identifying VEGF inhibition as a viable strategy to enhance #Immunotherapy in #SolidTumors. @harvardmed.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
Featured Article: Probiotics eradicate glioblastoma
E. coli Nissle produces bispecific engagers to recruit & instruct in situ-edited CAR macrophages. Microbe-guided CAR macrophages overcome glioblastoma antigenic heterogeneity & establish antitumor memory
www.cell.com/cell-host-mi...
E. coli Nissle produces bispecific engagers to recruit & instruct in situ-edited CAR macrophages. Microbe-guided CAR macrophages overcome glioblastoma antigenic heterogeneity & establish antitumor memory
www.cell.com/cell-host-mi...
Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice
Zhang et al. report a synthetic host-microbe immune circuit in which probiotics locally
produce bispecific engagers to recruit and instruct in situ-edited CAR macrophages.
Macrophage-microbe crosstalk...
www.cell.com
February 12, 2026 at 12:19 PM
Featured Article: Probiotics eradicate glioblastoma
E. coli Nissle produces bispecific engagers to recruit & instruct in situ-edited CAR macrophages. Microbe-guided CAR macrophages overcome glioblastoma antigenic heterogeneity & establish antitumor memory
www.cell.com/cell-host-mi...
E. coli Nissle produces bispecific engagers to recruit & instruct in situ-edited CAR macrophages. Microbe-guided CAR macrophages overcome glioblastoma antigenic heterogeneity & establish antitumor memory
www.cell.com/cell-host-mi...
On the front cover of RSCChemBio Issue 2: Oliver Seitz et al. introduce "DNA-programmed bispecific peptide assemblies for delivering cytotoxic payload to cells expressing EGFR and MET receptor"🧬 Read the full story now: doi.org/10.1039/D5CB...
👉 Get the full issue here: pubs.rsc.org/en/jour...
👉 Get the full issue here: pubs.rsc.org/en/jour...
February 12, 2026 at 11:35 AM
On the front cover of RSCChemBio Issue 2: Oliver Seitz et al. introduce "DNA-programmed bispecific peptide assemblies for delivering cytotoxic payload to cells expressing EGFR and MET receptor"🧬 Read the full story now: doi.org/10.1039/D5CB...
👉 Get the full issue here: pubs.rsc.org/en/jour...
👉 Get the full issue here: pubs.rsc.org/en/jour...
Integrated Cytotoxic and Safety Mechanism of IMV-M (TM), a MUC16 x DR5 Bispecific Antibody https://www.biorxiv.org/content/10.64898/2026.02.10.705083v1
February 12, 2026 at 5:52 AM
Integrated Cytotoxic and Safety Mechanism of IMV-M (TM), a MUC16 x DR5 Bispecific Antibody https://www.biorxiv.org/content/10.64898/2026.02.10.705083v1
Integrated Cytotoxic and Safety Mechanism of IMV-M (TM), a MUC16 x DR5 Bispecific Antibody https://www.biorxiv.org/content/10.64898/2026.02.10.705083v1
February 12, 2026 at 5:52 AM
Integrated Cytotoxic and Safety Mechanism of IMV-M (TM), a MUC16 x DR5 Bispecific Antibody https://www.biorxiv.org/content/10.64898/2026.02.10.705083v1
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
academic.oup.com/abt/article/...
#BispecificAntibody #PDL1 #VEGF
🎇🎇A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
academic.oup.com/abt/article/...
#BispecificAntibody #PDL1 #VEGF
A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
Statement of Significance This project developed CVL006, a PD-L1/VEGF bispecific antibody combining an anti-PD-L1 VHH domain with an anti-VEGF IgG1. Precli
academic.oup.com
February 11, 2026 at 1:38 PM
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
academic.oup.com/abt/article/...
#BispecificAntibody #PDL1 #VEGF
🎇🎇A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
academic.oup.com/abt/article/...
#BispecificAntibody #PDL1 #VEGF
WO2026025059 a Fc-engineered CD24×CD3 bispecific IgG antibodies targeting CD24-overexpressing solid and hematologic tumors. By attenuating Fc effector functions, they favor CD3-mediated T-cell cytotoxicity. Preclinical data show potent, dose-, CD24- and T-cell-dependent tumor killing.
[Credit: UoV]
[Credit: UoV]
February 11, 2026 at 12:39 PM
WO2026025059 a Fc-engineered CD24×CD3 bispecific IgG antibodies targeting CD24-overexpressing solid and hematologic tumors. By attenuating Fc effector functions, they favor CD3-mediated T-cell cytotoxicity. Preclinical data show potent, dose-, CD24- and T-cell-dependent tumor killing.
[Credit: UoV]
[Credit: UoV]
Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases#China#Hong_Kong#Akeso#bispecific_antibody#AK139
Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases
Akeso, Inc. has received approval for Phase II clinical trials for its bispecific antibody, AK139, which targets respiratory and autoimmune diseases, marking a significant advancement in treatment options.
third-news.com
February 11, 2026 at 9:07 AM
Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases#China#Hong_Kong#Akeso#bispecific_antibody#AK139
Bispecific Monoclonal Antibodies Market: Future Outlook and Trends 2035 www.wiseguyreports.com/reports/bisp...
Bispecific Monoclonal Antibodies Market: Future Outlook and Trends 2035
The Bispecific Monoclonal Antibodies Market Size was valued at 11.2 USD Billion in 2024. The Bispecific Monoclonal Antibodies Market is expected to grow from 12.3 USD Billion in 2025 to 30 USD Billion...
www.wiseguyreports.com
February 11, 2026 at 7:04 AM
Bispecific Monoclonal Antibodies Market: Future Outlook and Trends 2035 www.wiseguyreports.com/reports/bisp...
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
scientiasalut.gencat.cat
February 10, 2026 at 11:07 AM
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial scientiasalut.gencat.cat/handle/11351... #ScientiaVH
SHEDTACs are bispecific antibodies that bring endogenous membrane proteases (sheddases) into proximity with cell-surface targets to catalyze receptor proteolysis (shedding).
February 9, 2026 at 11:37 PM
SHEDTACs are bispecific antibodies that bring endogenous membrane proteases (sheddases) into proximity with cell-surface targets to catalyze receptor proteolysis (shedding).
SHEDTACs are bispecific antibodies that bring endogenous membrane proteases (sheddases) into proximity with cell-surface targets to catalyze receptor proteolysis (shedding).
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
February 9, 2026 at 10:37 PM
SHEDTACs are bispecific antibodies that bring endogenous membrane proteases (sheddases) into proximity with cell-surface targets to catalyze receptor proteolysis (shedding).
Save the date! Summit Therapeutics, Inc.s’ PD-1/VEGF bispecific ivonescimab now has an FDA decision date of November 14 for EGFR-mutant, locally advanced or metastatic non-squamous NSCLC. #lungcancer
www.biospace.com/fda/summits-...
www.biospace.com/fda/summits-...
Summit’s Potential Keytruda Rival Gets November FDA Decision Date
The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.
www.biospace.com
February 9, 2026 at 2:03 PM
Save the date! Summit Therapeutics, Inc.s’ PD-1/VEGF bispecific ivonescimab now has an FDA decision date of November 14 for EGFR-mutant, locally advanced or metastatic non-squamous NSCLC. #lungcancer
www.biospace.com/fda/summits-...
www.biospace.com/fda/summits-...
Top biotech deals in January 2026
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
Top biotech deals in January 2026
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January 2026 No holiday hangover has stopped the biopharma industry from striking partnerships in January. The new year commenced with American pharma giant Amgen’s $840 million buyout of British biotech Dark Blue Therapeutics.
nexttech-news.com
February 8, 2026 at 1:35 PM
Top biotech deals in January 2026
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
Top biotech deals in January 2026
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
Top biotech deals in January 2026
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January 2026 No holiday hangover has stopped the biopharma industry from striking partnerships in January. The new year commenced with American pharma giant Amgen’s $840 million buyout of British biotech Dark Blue Therapeutics.
nexttech-news.com
February 8, 2026 at 1:35 PM
Top biotech deals in January 2026
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
January 2026 saw fewer mergers and acquisitions (M&As) hit the biopharma industry. However, sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the licensing deals arena last month. Top biotech M&As of January…
Zenocutuzumab, the first-in-class HER2/HER3 bispecific, has shown durable responses and meaningful progression-free survival in the phase 2 eNRGy trial for NRG1 fusion–positive advanced NSCLC. #lungcancer
www.oncologynewscentral.com/nsclc/first-...
www.oncologynewscentral.com/nsclc/first-...
First-in-Class Bispecific Posts Strong Data in Phase 2 NSCLC Trial
Findings from the ongoing, open-label, single-group phase 2 eNRGy trial were presented in December at the 2025 North America Conference on Lung Cancer (NACLC).
www.oncologynewscentral.com
February 7, 2026 at 3:03 PM
Zenocutuzumab, the first-in-class HER2/HER3 bispecific, has shown durable responses and meaningful progression-free survival in the phase 2 eNRGy trial for NRG1 fusion–positive advanced NSCLC. #lungcancer
www.oncologynewscentral.com/nsclc/first-...
www.oncologynewscentral.com/nsclc/first-...
🩸 More insights on bispecific antibody mechanisms and clinical development in Multiple Myeloma
#MultipleMyeloma #BispecificAntibodies #Immunotherapy #CancerImmunotherapy #GPRC5D #FcRH5 #TrispecificAntibodies #AntigenEscape #HemeOnc #HEMEHUB
#MultipleMyeloma #BispecificAntibodies #Immunotherapy #CancerImmunotherapy #GPRC5D #FcRH5 #TrispecificAntibodies #AntigenEscape #HemeOnc #HEMEHUB
February 6, 2026 at 10:58 PM
🩸 More insights on bispecific antibody mechanisms and clinical development in Multiple Myeloma
#MultipleMyeloma #BispecificAntibodies #Immunotherapy #CancerImmunotherapy #GPRC5D #FcRH5 #TrispecificAntibodies #AntigenEscape #HemeOnc #HEMEHUB
#MultipleMyeloma #BispecificAntibodies #Immunotherapy #CancerImmunotherapy #GPRC5D #FcRH5 #TrispecificAntibodies #AntigenEscape #HemeOnc #HEMEHUB
🩸Facts about Multiple Myeloma:
Bispecific Antibodies (BsAbs) – Mechanism and Approval
#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd
Bispecific Antibodies (BsAbs) – Mechanism and Approval
#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd
February 5, 2026 at 3:30 AM
🩸Facts about Multiple Myeloma:
Bispecific Antibodies (BsAbs) – Mechanism and Approval
#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd
Bispecific Antibodies (BsAbs) – Mechanism and Approval
#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd
NKG2A antibody blockade and bispecific NKG2A engagers enhance NK and T cell antitumor activity
www.science.org/doi/10.1126/...
@idpittstop.bsky.social
www.science.org/doi/10.1126/...
@idpittstop.bsky.social
February 5, 2026 at 1:13 AM
NKG2A antibody blockade and bispecific NKG2A engagers enhance NK and T cell antitumor activity
www.science.org/doi/10.1126/...
@idpittstop.bsky.social
www.science.org/doi/10.1126/...
@idpittstop.bsky.social
This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back.
Read the open access review: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
Read the open access review: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
February 4, 2026 at 6:07 PM
This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back.
Read the open access review: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
Read the open access review: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back.
Read the open access review here: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
Read the open access review here: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
February 4, 2026 at 2:24 PM
This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back.
Read the open access review here: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
Read the open access review here: https://bit.ly/4291Ipg
#CancerResearch #Immunotherapy #BiTEs
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial www.nature.com/articles/s41... #hvhebron #malinf [Text complet]
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial - Nature Communications
Although antiretroviral therapies (ART) have expanded the life expectancy of patients with HIV, they are not curative due to the presence of latently infected cells. Here, the authors present IMC-M113...
www.nature.com
February 4, 2026 at 12:48 PM
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial www.nature.com/articles/s41... #hvhebron #malinf [Text complet]
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
February 3, 2026 at 8:32 PM
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
Bispecific engagers targeting the CεmX domain of membrane-bound IgE for depletion of IgE-producing cells in allergic disease
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
February 3, 2026 at 8:19 PM
Bispecific engagers targeting the CεmX domain of membrane-bound IgE for depletion of IgE-producing cells in allergic disease
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...